Abstract: The present invention provides topical dosages and formulations of lidocaine and pharmaceutically acceptable salts thereof, which are efficacious, chemically stable and physiologically balanced for safety and efficacy, particularly for debridement pain, and increase the duration of pain relief, and thereby provide more effective treatment to chronic open wounds, particularly those in non-mucosal tissue.
Abstract: Provided is a pharmaceutical formulation and a method associated therewith for treating bacterial vaginosis. The pharmaceutical formulation includes from 10 to 25 weight parts of poloxamer F127, from 0.5 to 3.0 weight parts of xanthan gum, from 70 to 90 weight parts of water, and a therapeutically effective amount of a pharmaceutical active ingredient. The pharmaceutical formulation may also include from 0.5 to 1.5 weight parts of benzyl alcohol.
Abstract: Provided are bioerodible compositions that can be implanted into cavities or mammalian tissue as a liquid or semi-liquid and which solidify upon exposure of the body temperature of the mammal. The implants erode over a prescribed period of time and elute a drug. The implants also form a seal with the skin or mucosa surrounding the cavity to prevent the entry of bacterial pathogens.
Type:
Grant
Filed:
July 12, 2013
Date of Patent:
April 8, 2014
Assignee:
Trilogic Pharma LLC
Inventors:
Hemant H. Alur, James A. H. Harwick, Pravakar Mondal, Thomas P. Johnston
Abstract: Provided are bioerodible compositions that can be implanted into cavities of mammalian tissue as a liquid or semi-liquid and which solidify upon exposure to body temperature of the mammal. The implants erode over a prescribed period of time and elute a drug. The implants also form a seal with the skin or mucosa surrounding the cavity to prevent the entry of bacterial pathogens.
Type:
Grant
Filed:
December 2, 2008
Date of Patent:
August 6, 2013
Assignee:
TriLogic Pharma LLC
Inventors:
Hemant H. Alur, James A. H. Harwick, Pravakar Mondal, Thomas P. Johnston
Abstract: Provided are bioerodible compositions that can be implanted into cavities of mammalian tissue as a liquid or semi-liquid and which solidify upon exposure to body temperature of the mammal. The implants erode over a prescribed period of time and elute a drug. The implants also form a seal with the skin or mucosa surrounding the cavity to prevent the entry of bacterial pathogens.
Type:
Application
Filed:
December 2, 2008
Publication date:
December 23, 2010
Applicant:
TriLogic Pharma LLC
Inventors:
Hemant H. Alur, James A.H. Harwick, Pravakar Mondal, Thomas P. Johnston
© 2025 Justia
